Savitz Ryan sold $3.2M of DNTH
Savitz Ryan (EVP, CFO & CBO) sold 31,249 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.03 ($100.22–$101.97, $3.16M total) across 3 trades on 2026-07-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale size, price range, and that it was executed under a pre-arranged Rule 10b5-1 plan, with holdings after the transaction reported as 0 shares.
Market read
Primarily a sentiment/positioning datapoint for DNTH, with limited direct trading signal absent any accompanying fundamental news.
What to watch
Traders may overreact to insider sales; the key is whether there are concurrent disclosures (financing, trial updates, guidance) which are not present here.
Background
The article is an SEC Form 4 insider transaction for Dianthus Therapeutics, Inc. (DNTH) reported by an officer (EVP, CFO & CBO).
Ticker impact
DNTH CFO and CBO Savitz Ryan sold 31,249 shares in open-market trades totaling about $3.16M under a 10b5-1 plan.
Likely limited, short-lived impact unless paired with other negative catalysts.
The filing is a routine Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no new operational or financial guidance disclosed.
Market effects
Minimal sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
10b5-1 plans are often used to reduce timing risk, so the sale may not signal bearish fundamentals.
Key entities
- issuerDianthus Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderSavitz Ryan
EVP, CFO & CBO who sold 31,249 DNTH shares across three trades.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan cited as Yes, indicating the sale timing was predetermined.
